IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Self-Nanoemulsifying Drug Delivery Systems (SNEDDS): Optimisation Strategies, Mechanisms And Applications In Oral Drug Delivery

Mr. Mohammad Zishan Ibrahim[1] Mr. Gajanan Ghorpade[2], Dr. Jameel Ahmed [3]
Assistant Professor[1], Research Scholor [2], Principal[3]
Department of Pharmaceutics, Kandhar College of Pharmacy, Nanded, Maharashtra, India

1. Introduction

1.1 Overview of drug solubility and bioavailability challenges

Oral drug delivery remains the most preferred route for drug administration due to its convenience, cost-effectiveness, and high patient compliance. However, a major challenge in oral drug delivery is the poor aqueous solubility and limited bioavailability of many newly developed drugs. Nearly 40–60% of new chemical entities (NCEs) belong to Biopharmaceutical Classification System (BCS) Class II and IV, characterized by low solubility and/or permeability. Poor solubility leads to erratic absorption, delayed onset of action, and variable therapeutic outcomes.

Conventional oral formulations such as tablets and capsules often fail to achieve adequate systemic exposure for lipophilic drugs, as dissolution in the gastrointestinal (GI) fluids becomes the rate-limiting step. In response to these challenges, lipid-based formulations (LBFs**)** have emerged as promising alternatives, offering improved solubilization and lymphatic transport.

Among these systems, Self-Emulsifying Drug Delivery Systems (SEDDS**)** and their advanced versions, Self-Nanoemulsifying Drug Delivery Systems (SNEDDS)**,** have gained significant attention. SNEDDS are isotropic mixtures of oils, surfactants, and co-surfactants that spontaneously form fine oil-in-water nanoemulsions upon mild agitation in the GI fluids. Compared with conventional formulations, SNEDDS provide enhanced solubility, protection from degradation, and improved bioavailability of lipophilic drugs.

A significant challenge in oral drug delivery is the poor aqueous solubility of many active pharmaceutical ingredients (APIs). Nearly 40–70% of new chemical entities (NCEs) are poorly water-soluble, leading to limited dissolution, variable absorption, and low bioavailability (Akhlaq et al., 2021). These drugs often exhibit inconsistent plasma concentrations, reduced therapeutic efficacy, and unpredictable pharmacokinetics. In addition, factors such as gastrointestinal (GI) pH variability, enzymatic degradation, and first-pass metabolism further reduce systemic availability, making solubility enhancement a key focus of modern formulation research (Ravi et al., 2023).

1.2 Limitations of conventional oral drug delivery systems

Conventional dosage forms such as tablets, capsules, and suspensions rely heavily on the dissolution of the drug in GI fluids prior to absorption. For lipophilic drugs, this step can be a major rate-limiting barrier, leading to poor and inconsistent absorption (Haarika et al., 2023). Moreover, conventional systems often suffer from food dependency, precipitation of the drug upon dilution, and significant inter-individual variability in absorption. These drawbacks limit the ability to achieve optimal therapeutic concentrations and may necessitate higher or more frequent dosing.

1.3 Emergence of lipid-based formulations

Lipid-based drug delivery systems (LBDDS) have emerged as an effective strategy to enhance the oral absorption of poorly soluble compounds. By incorporating oils, surfactants, and co-solvents, these systems can maintain drugs in a solubilized state, improve intestinal lymphatic transport, and reduce first-pass metabolism (Akhlaq et al., 2021). Additionally, lipid systems promote self-dispersion within the GI tract, enabling better bioavailability and reduced food effects.

1.4 Introduction to SEDDS and SNEDDS

Self-emulsifying drug delivery systems (SEDDS) are isotropic mixtures of oils, surfactants, and co-surfactants that form emulsions spontaneously when exposed to aqueous environments under gentle agitation. A more advanced variant, the self-nanoemulsifying drug delivery system (SNEDDS), forms fine oil-in-water nanoemulsions with droplet sizes typically below 200 nm upon dilution (Haarika et al., 2023). These nano-sized droplets provide a large surface area for absorption and can significantly improve drug dissolution and permeability in the intestinal lumen (Ravi et al., 2023).

1.5 Advantages of SNEDDS over conventional formulations

SNEDDS offer multiple benefits compared to conventional dosage forms and even traditional lipid formulations. They maintain the drug in a solubilized form, reducing precipitation risk and improving absorption consistency (Kannan et al., 2023). The nano-sized droplets ensure enhanced surface area and efficient partitioning across biological membranes, while spontaneous emulsification reduces the dependency on physiological bile salts or food for effective absorption. Furthermore, SNEDDS can be filled into capsules or transformed into solid forms (solid SNEDDS), improving stability, handling, and patient compliance (Pharmaceuticals, 2023). These attributes make SNEDDS particularly advantageous for Biopharmaceutics Classification System (BCS) Class II and IV drugs.

2. Theoretical Background of SNEDDS

2.1 Definition and Concept

Self-nanoemulsifying drug delivery systems (SNEDDS) are isotropic mixtures of oil, surfactant, and co-surfactant that can spontaneously form fine oil-in-water nanoemulsions upon mild agitation and dilution in the gastrointestinal (GI) fluids (Pouton, 1997). The agitation provided by gastric motility is sufficient to disperse the formulation, generating nano-sized droplets typically below 100 nm in diameter (Shah et al., 1994).

Unlike conventional emulsions that require mechanical energy, SNEDDS rely on a spontaneous emulsification process driven by interfacial tension reduction between the oil and aqueous phases (Porter et al., 2007). The optimal balance of surfactant and co-surfactant concentrations enables this spontaneous emulsification upon contact with GI fluids, resulting in a stable, transparent or slightly bluish nanoemulsion.

2.2 Mechanism of Self-Nanoemulsification: Thermodynamic and Kinetic Aspects

The formation of SNEDDS nanoemulsions is governed by both thermodynamic and kinetic principles. Emulsion formation generally requires an input of free energy (ΔG) to create an interface between immiscible phases, making it thermodynamically unfavorable. However, in SNEDDS, surfactants and co-surfactants significantly reduce the interfacial tension, minimizing ΔG and facilitating spontaneous emulsification (Kommuru et al., 2001). The resulting interfacial film prevents droplet coalescence and stabilizes the nanoemulsion.

Although nanoemulsions are not thermodynamically stable, they exhibit high kinetic stability. The surfactant layer surrounding the droplets and their very small size inhibit phase separation and droplet aggregation (Constantinides, 1995). The rate of emulsification is influenced by the surfactant diffusion rate, viscosity of the formulation, and hydrodynamic conditions in the GI tract. Consequently, careful selection of formulation components ensures both rapid emulsification and long-term kinetic stability.

2.3 Composition and Structure of Nanoemulsions

A typical SNEDDS formulation comprises three essential components:

1. **Oil phase:** Solubilizes lipophilic drugs and promotes absorption through lymphatic transport.
2. **Surfactant:** Reduces interfacial tension and stabilizes droplets by forming a protective monolayer.
3. **Co-surfactant or co-solvent:** Enhances interfacial fluidity and facilitates spontaneous emulsification (Balakrishnan et al., 2009).

Upon dilution, these components self-assemble to form spherical droplets with a hydrophobic core and a hydrophilic shell**.** The nanoscale size of these droplets provides a large interfacial area, which improves drug dissolution and absorption efficiency (Singh et al., 2009).

2.4 Types of Lipid-Based Self-Emulsifying Systems

Lipid-based formulations are classified based on droplet size, appearance, and emulsification properties:

System	Full Form	Average Droplet Size	Appearance	Relative Stability
SEDDS	Self-Emulsifying Drug Delivery System	> 250 nm	Opaque or milky	Moderate
SMEDDS	Self-Microemulsifying Drug Delivery System	100–250 nm	Slightly translucent	High
SNEDDS	Self-Nanoemulsifying Drug Delivery System	< 100 nm	Clear or transparent	Very high

Among these, SNEDDS represent the most advanced class because the nano-sized droplets offer enhanced surface area, greater kinetic stability, and superior drug absorption compared with SEDDS or SMEDDS (Date et al., 2010). These characteristics make SNEDDS particularly suitable for delivering poorly water-soluble drugs with improved oral bioavailability.

3. Formulation Components of SNEDDS

The performance of a self-nanoemulsifying drug delivery system (SNEDDS) is highly dependent on the selection and ratio of its formulation components. A typical SNEDDS consists of an oil phase, surfactant, co-surfactant (or co-solvent), and the active pharmaceutical ingredient (API). Each component plays a critical role in self-emulsification efficiency, stability, and bioavailability enhancement.

3.1 Oils

The oil phase serves as a solvent for lipophilic drugs and facilitates their absorption via the lymphatic system, bypassing first-pass metabolism (Porter et al., 2007). Oils are broadly categorized into:

- **Medium-chain triglycerides (MCTs):** e.g., Caprylic/capric triglycerides (Capryol 90, Labrafac), known for rapid digestion and efficient self-emulsification.
- **Long-chain triglycerides (LCTs):** provide better lymphatic transport but slower emulsification compared with MCTs.
- **Novel lipid excipients:** including mono- and diglycerides, or synthetic lipids designed to improve solubility and formulation stability.

The choice of oil is critical as it determines drug solubility, droplet size, and the rate of emulsification (Kommuru et al., 2001).

3.2 Surfactants

Surfactants stabilize the oil–water interface and reduce interfacial tension, promoting spontaneous formation of nanoemulsions upon contact with aqueous media. Nonionic surfactants are preferred for SNEDDS due to lower toxicity and GI irritancy. Common surfactants include:

- Tween 20, Tween 80
- Cremophor EL, Cremophor RH40
- Labrasol

The hydrophilic–lipophilic balance (HLB) value of the surfactant is a critical factor. Surfactants with high HLB (>12) are generally used for o/w nanoemulsions, ensuring rapid emulsification and droplet stability (Date et al., 2010).

3.3 Co-Surfactants / Co-Solvents

Co-surfactants or co-solvents are included to increase interfacial fluidity and solubilization capacity, assisting in spontaneous emulsification. Commonly used co-surfactants include:

- Polyethylene glycol (PEG 400)
- Ethanol
- Propylene glycol
- Transcutol P

These agents also help improve the solubility of lipophilic drugs in the SNEDDS preconcentrate, facilitating higher drug loading (Balakrishnan et al., 2009).

3.4 Drug Loading and Solubility Studies

The drug must be completely soluble in the preconcentrate to avoid precipitation upon dilution in GI fluids. Solubility studies are conducted in various oils, surfactants, and co-surfactants to select the most suitable excipient combination.

High drug loading is achievable if the solubility of the drug in the SNEDDS system is higher than its required dose, and the excipients do not precipitate upon dilution (Singh et al., 2009).

3.5 Excipient Screening

Effective SNEDDS formulation requires systematic screening of excipients based on:

- **Solubility:** Ability to dissolve sufficient drug quantity.
- **Emulsification efficiency:** Capability to form a stable nanoemulsion quickly upon dilution.
- **Compatibility:** No chemical interaction between drug and excipients.

Phase diagrams and solubility studies are commonly used to optimize the ratios of oil, surfactant, and co-surfactant to achieve stable and reproducible self-nanoemulsifying systems (Pouton, 1997).

4. Formulation Strategies and Optimization of SNEDDS

Formulation strategies for self-nanoemulsifying drug delivery systems (SNEDDS) aim to maximize drug solubility, improve bioavailability, and ensure physical and chemical stability. Optimization involves systematic selection of excipients, determination of their ratios, and validation through analytical and experimental methods.

4.1 Phase Diagram Studies

Pseudo-ternary phase diagrams are essential in mapping the self-emulsification region of SNEDDS formulations. These diagrams evaluate combinations of oil, surfactant, and co-surfactant, indicating the ratios that spontaneously form stable nanoemulsions upon dilution with aqueous media (Pouton, 2006).

Benefits of phase diagram studies:

- Identify the nanoemulsion region where rapid self-emulsification occurs.
- Avoid drug precipitation and phase separation by eliminating unstable compositions.
- Reduce trial-and-error formulation development.

Researchers often combine ternary diagrams with solubility data to identify the most promising excipient combinations for target drug loading.

4.2 Design of Experiments (DoE) Approaches

DoE enables statistical and systematic optimization of SNEDDS formulations. Instead of changing one variable at a time, DoE allows multiple factors—such as oil type, surfactant/co-surfactant ratio, and drug loading—to be studied simultaneously. Common DoE models include:

- **Full factorial design:** Studies all possible combinations of factors.
- **Central composite design (CCD):** Explores nonlinear relationships between variables.
- **Response surface methodology (RSM):** Predicts optimum formulation conditions.

DoE optimizes key quality attributes including droplet size, PDI, self-emulsification time, and stability, minimizing experimental workload and improving reproducibility (Date et al., 2010).

4.3 Droplet Size and Polydispersity Index (PDI)

Droplet size is a major determinant of oral bioavailability. Smaller droplets provide:

- **Increased surface area** for faster drug release.
- **Improved absorption** via enhanced contact with the gastrointestinal epithelium.
- **Enhanced lymphatic transport**, bypassing hepatic first-pass metabolism.

PDI indicates droplet size uniformity. A PDI below 0.3 is desirable for homogeneous nanoemulsions, while values above 0.5 suggest polydisperse systems prone to instability (Singh et al., 2009).

4.4 Thermodynamic Stability Testing

SNEDDS must demonstrate physical stability under various stress conditions to ensure robustness. Standard stability tests include:

- **Centrifugation:** Detects phase separation or creaming.
- **Heating–cooling cycles:** Evaluates stability under thermal stress.
- **Freeze–thaw cycles:** Assesses precipitation or crystallization.
- **Long-term storage studies:** Confirms stability under ambient or accelerated conditions.

Thermodynamically stable formulations reduce risk of drug precipitation, ensuring consistent in vivo performance (Kommuru et al., 2001).

4.5 Solidification Approaches

Converting liquid SNEDDS into solid dosage forms (S-SNEDDS) addresses issues such as leakage, handling, and stability. Techniques include:

- **Adsorption onto solid carriers:** Silica, magnesium aluminometasilicate, or microcrystalline cellulose.
- **Spray drying:** Converts liquid SNEDDS into powders.
- **Melt granulation or extrusion:** Forms tablets or pellets.
- **Capsule filling:** Encapsulates liquid SNEDDS directly.

Solid SNEDDS retain the self-emulsifying property upon contact with aqueous media, making them suitable for tablets, capsules, pellets, and multiparticulate systems (Tang et al., 2008).

4.6 Advanced Optimization Strategies

Beyond conventional approaches, modern SNEDDS development integrates:

- **Quality by Design (QbD):** Defines critical quality attributes (CQAs) and critical process parameters (CPPs) to ensure batch-to-batch consistency.
- **Computational modeling:** Predicts droplet formation, solubility, and emulsification behavior using molecular dynamics simulations.
- **Artificial intelligence (AI):** Assists in excipient selection, ratio optimization, and predicting nanoemulsion stability, reducing experimental iterations.

These tools enhance the efficiency, reproducibility, and predictability of SNEDDS formulation development.

4.7 Optimization Challenges

While SNEDDS offers significant advantages, formulation optimization faces challenges:

- **Drug precipitation:** Occurs if drug solubility is exceeded upon dilution.
- **Surfactant toxicity:** High surfactant concentrations may cause GI irritation.
- **Scale-up issues:** Maintaining nanoemulsion droplet size and homogeneity at industrial scale.
- **Stability:** Certain lipids or co-solvents may degrade during storage.

Addressing these challenges requires comprehensive excipient screening, robust stability testing, and predictive optimization tools (Pouton, 2006; Date et al., 2010).

5. Characterization of SNEDDS

Characterization of self-nanoemulsifying drug delivery systems (SNEDDS) is a critical step in formulation development, ensuring quality, reproducibility, stability, and in vivo performance. A combination of physicochemical, in vitro, and in vivo evaluations is essential to confirm that the formulation meets the desired specifications and provides enhanced oral bioavailability.

5.1 Visual Assessment and Self-Emulsification Time

Visual assessment is the first qualitative evaluation of SNEDDS and involves observing the physical appearance of the formulation upon dilution in aqueous media. A well-formulated SNEDDS should spontaneously form a clear, transparent, or slightly opalescent nanoemulsion without requiring external energy input such as shaking or stirring. The appearance provides initial insight into the homogeneity, emulsification efficiency, and stability of the system.

Self-emulsification time is another critical parameter, representing the time required for a SNEDDS formulation to form a homogenous emulsion when introduced into aqueous media under gentle agitation. A rapid emulsification time (typically less than 1–2 minutes) ensures immediate drug availability for absorption in the gastrointestinal tract. Longer emulsification times may indicate insufficient surfactant concentration, inappropriate oil-to-surfactant ratio, or poor miscibility, which can negatively affect drug dissolution and bioavailability.

Example: In a study by Pouton (2006), SNEDDS formulations of poorly soluble drugs achieved self-emulsification within 30–60 seconds, forming stable nanoemulsions that remained homogeneous for several hours.

5.2 Droplet Size Analysis

Droplet size is a critical parameter influencing drug solubilization, release rate, absorption, and overall bioavailability. Smaller droplets provide a larger interfacial surface area, promoting faster drug dissolution and better contact with the intestinal epithelium, thereby facilitating efficient drug absorption. Droplet size is typically measured after diluting SNEDDS in aqueous media under controlled conditions.

Techniques commonly used for droplet size analysis include:

- **Dynamic Light Scattering (DLS):** Provides precise measurements of mean droplet size and polydispersity index (PDI).
- **Transmission Electron Microscopy (TEM):** Offers high-resolution images to evaluate droplet morphology and confirm the presence of nano-sized droplets.
- **Scanning Electron Microscopy (SEM):** Particularly useful for solidified SNEDDS (S-SNEDDS), allowing visualization of particle surface morphology and aggregation.

A low PDI (<0.3) indicates narrow droplet size distribution, which is essential for formulation stability. High PDI values suggest polydispersity and potential for droplet coalescence, leading to instability (Singh et al., 2009). Optimizing droplet size and uniformity is critical to achieving consistent drug release and predictable in vivo performance.

5.3 Zeta Potential Measurement

Zeta potential measures the surface electrical charge of droplets in the nanoemulsion and serves as an indicator of physical stability. High absolute zeta potential values (either positive or negative) result in electrostatic repulsion between droplets, reducing the likelihood of aggregation and phase separation during storage.

While many SNEDDS use nonionic surfactants, which rely on steric stabilization rather than charge stabilization, zeta potential measurement is still important, especially for systems containing ionic surfactants or co-surfactants. Stable formulations typically show zeta potential values above ±30 mV, indicating sufficient repulsive forces to prevent droplet coalescence (Singh et al., 2009).

Zeta potential also influences in vivo behavior, as surface charge can affect interaction with intestinal mucosa, uptake by enterocytes, and lymphatic transport. Formulations with optimized zeta potential often demonstrate enhanced bioavailability and prolonged circulation times.

5.4 Thermodynamic Stability Testing

Thermodynamic stability testing ensures that SNEDDS formulations remain stable under physical and environmental stress conditions, confirming that they are robust for both storage and in vivo application. Typical stability tests include:

- **Centrifugation:** Detects phase separation, creaming, or sedimentation, indicating instability in droplet dispersion.
- **Heating–cooling cycles:** Expose the formulation to repeated temperature fluctuations, simulating storage or environmental changes.
- **Freeze–thaw cycles:** Evaluate resistance to precipitation or crystallization when the formulation undergoes freezing and subsequent thawing.

Formulations that remain clear, homogeneous, and free of precipitation after these tests are considered thermodynamically stable. Stability testing also provides insight into long-term storage potential and robustness under varying physiological conditions (Kommuru et al., 2001).

5.5 In Vitro Dissolution and Diffusion Studies

In vitro dissolution studies assess the rate and extent of drug release from SNEDDS formulations in simulated gastrointestinal conditions. These studies are particularly important for poorly water-soluble drugs, as they provide insight into how SNEDDS enhances solubilization and prevents drug precipitation.

Diffusion studies further evaluate drug permeation across biological membranes, typically using dialysis membranes or Franz diffusion cells. They help predict oral absorption and bioavailability by simulating drug transport across the intestinal epithelium.

The combination of dissolution and diffusion studies allows researchers to screen multiple formulations efficiently, identify optimal compositions, and correlate in vitro performance with expected in vivo outcomes (Date et al., 2010).

5.6 In Vivo Bioavailability and Pharmacokinetic Evaluation

The ultimate goal of SNEDDS is enhanced oral bioavailability, especially for BCS class II and IV drugs with poor solubility or extensive first-pass metabolism. In vivo studies involve:

- Measurement of plasma drug concentration-time profiles.
- Calculation of pharmacokinetic parameters such as C_max, T_max, and AUC.
- Comparison with conventional formulations or drug suspensions.

SNEDDS improve bioavailability through multiple mechanisms: increased solubilization, enhanced intestinal permeability, protection against degradation, and promotion of lymphatic transport, bypassing first-pass metabolism. Several marketed formulations, including Neoral® (cyclosporine), Fortovase® (saquinavir), and Norvir® (ritonavir), demonstrate significant bioavailability enhancement via SNEDDS (Tang et al., 2008; Date et al., 2010).

6. Mechanism of Drug Absorption Enhancement

Self-nanoemulsifying drug delivery systems (SNEDDS) enhance oral drug absorption through multiple complementary mechanisms, including increased solubilization, improved intestinal permeability, bypassing of first-pass metabolism, and promotion of lymphatic transport. These mechanisms collectively lead to higher bioavailability of poorly water-soluble drugs, particularly those belonging to BCS class II and IV.

6.1 Role of Nano-Sized Droplets and Increased Surface Area

One of the fundamental features of SNEDDS is the formation of nano-sized droplets (typically 20–200 nm) upon contact with gastrointestinal fluids. The small droplet size dramatically increases the surface area available for drug dissolution and absorption, enabling rapid drug release and improved solubilization.

- Nanoemulsion droplets maintain the drug in a solubilized state, preventing precipitation in the intestinal lumen.
- The high surface area ensures close contact between the drug-loaded droplets and the enterocyte membrane, facilitating passive diffusion.
- Smaller droplets also promote faster dispersion in gastrointestinal fluids, reducing the time required for drug absorption (Date et al., 2010).

By maintaining the drug in a thermodynamically stable, solubilized form, SNEDDS overcome the primary limitation of poorly soluble drugs: insufficient dissolution in the aqueous gastrointestinal environment.

6.2 Bypassing First-Pass Metabolism

Another key mechanism by which SNEDDS improve bioavailability is bypassing hepatic first-pass metabolism. Certain lipid-based formulations enable the drug to be absorbed via the intestinal lymphatic system, rather than the portal blood system, which carries drugs directly to the liver.

- Drugs transported through lymphatic pathways avoid extensive metabolism in the liver, resulting in higher systemic drug concentrations.
- This is particularly important for drugs with high hepatic extraction ratios, such as cyclosporine and ritonavir, which exhibit significant degradation when absorbed via the conventional portal circulation (Tang et al., 2008).

By altering the absorption route, SNEDDS can significantly increase systemic exposure and therapeutic efficacy without increasing the administered dose.

6.3 Enhanced Lymphatic Transport

Lipophilic drugs formulated in SNEDDS can associate with dietary lipids, forming chylomicrons in the enterocytes. This process facilitates transport through the lymphatic system, providing an alternative pathway to systemic circulation.

- Medium- and long-chain triglycerides used in SNEDDS promote the formation of chylomicrons, which carry drug molecules via the lymph.
- Lymphatic transport reduces first-pass metabolism, prolongs circulation time, and enhances overall bioavailability.
- This mechanism is particularly effective for highly lipophilic drugs (log P > 5) that readily partition into lipid-rich systems (Kommuru et al., 2001).

6.4 Improved Membrane Permeability

SNEDDS can also enhance drug absorption by modulating intestinal membrane permeability. Surfactants and co-surfactants present in SNEDDS play a significant role in altering the lipid bilayer of epithelial cell membranes, leading to:

- Increased drug permeation through tight junctions.
- Enhanced transcellular transport by promoting drug partitioning into the cell membrane.
- Temporary inhibition of efflux transporters, such as P-glycoprotein (P-gp), which often limit oral drug absorption (Date et al., 2010).

This combination of enhanced solubility and permeability ensures that a higher proportion of the administered dose reaches systemic circulation.

6.5 Protection Against Gastrointestinal Degradation

Certain drugs are susceptible to enzymatic degradation or hydrolysis in the gastrointestinal tract, limiting their oral bioavailability. SNEDDS can provide a protective lipidic microenvironment, which shields the drug from:

- Acidic pH in the stomach
- Enzymatic hydrolysis (e.g., proteases for peptide drugs)
- Oxidation or chemical degradation

This protection allows more intact drug molecules to reach the absorptive surfaces of the small intestine, further enhancing bioavailability.

7. Applications of SNEDDS

Self-nanoemulsifying drug delivery systems (SNEDDS) have emerged as a versatile and effective oral drug delivery platform, particularly for poorly water-soluble drugs. Their unique ability to spontaneously form nanoemulsions in the gastrointestinal tract provides enhanced solubilization, improved permeability, lymphatic transport, and bypass of first-pass metabolism. Over the past decades, SNEDDS have been applied in a wide spectrum of pharmaceutical formulations, ranging from conventional small molecules to peptides, herbal drugs, and advanced targeted therapies. This section provides a detailed overview of the applications of SNEDDS, highlighting their impact on drug bioavailability, therapeutic efficacy, and emerging areas of research.

7.1 Improved Bioavailability of BCS Class II and IV Drugs

One of the most significant applications of SNEDDS is the enhancement of oral bioavailability of poorly water-soluble drugs, especially those classified under the Biopharmaceutical Classification System (BCS) classes II and IV.

- BCS Class II drugs are poorly soluble but highly permeable. Their absorption is often limited by dissolution rate in the gastrointestinal fluids. SNEDDS maintain these drugs in a solubilized, nano-sized form, significantly improving the rate and extent of absorption.
- BCS Class IV drugs exhibit both poor solubility and poor permeability. SNEDDS address both challenges by combining enhanced solubilization with improved membrane permeability, often through surfactants and co-surfactants that facilitate paracellular or transcellular transport (Date et al., 2010).

Examples of BCS Class II drugs successfully formulated in SNEDDS include:

- **Fenofibrate** – lipid-based SNEDDS increased oral bioavailability by 2–3 fold compared to conventional tablets.
- **Ibuprofen** – SNEDDS formulations demonstrated faster absorption and higher peak plasma concentration.
- **Ritonavir** – commercial SNEDDS (Norvir®) enhanced solubility and systemic exposure in HIV therapy.

For BCS Class IV drugs, SNEDDS have been utilized to improve both solubility and permeability, making oral administration feasible for drugs that were otherwise poorly absorbed (Kommuru et al., 2001).

7.2 Marketed Formulations

Several SNEDDS-based products have been successfully commercialized, demonstrating their clinical utility and regulatory acceptance. These marketed formulations serve as examples of successful translation from laboratory research to clinical application:

1. **Neoral® (cyclosporine)**
   - Indicated for organ transplant patients to prevent rejection.
   - SNEDDS formulation improves solubility and bioavailability compared to conventional cyclosporine capsules (Tang et al., 2008).
2. **Fortovase® (saquinavir)**
   - Anti-HIV protease inhibitor with poor water solubility.
   - SNEDDS enhances oral absorption and reduces variability in plasma concentrations.
3. **Norvir® (ritonavir)**
   - Formulated as a soft-gel SNEDDS capsule.
   - Provides significantly improved solubility and systemic exposure, essential for effective HIV therapy.
4. **Neoral® vs Sandimmune®**
   - Comparison of SNEDDS-based Neoral® with conventional Sandimmune® highlights reduced inter- and intra-patient variability, faster absorption, and improved therapeutic outcomes (Pouton, 2006).

These examples demonstrate that SNEDDS can overcome solubility-limited absorption, ensuring predictable and reliable pharmacokinetics, which is critical for drugs with narrow therapeutic windows.

7.3 Applications in Peptides and Proteins

Peptides and protein therapeutics face significant challenges for oral delivery, including enzymatic degradation in the stomach, poor permeability across the intestinal epithelium, and low solubility. SNEDDS have shown potential to enhance oral delivery of macromolecules:

- **Protection from enzymatic degradation:** The lipidic environment of SNEDDS shields peptide drugs from **p**roteases in the GI tract, enhancing stability.
- **Enhanced absorption via lymphatic transport:** Lipid-based nanoemulsions promote intestinal uptake and lymphatic transport, bypassing first-pass metabolism and increasing systemic exposure.
- **Improved permeability:** Surfactants in SNEDDS can modulate epithelial tight junctions or inhibit efflux transporters, enhancing transcellular and paracellular transport of peptide drugs.

Examples include:

- **Insulin-loaded SNEDDS:** Studies demonstrated increased oral bioavailability in animal models compared to conventional solutions or suspensions.
- **Calcitonin and vasopressin:** Encapsulation in SNEDDS improved stability against enzymatic degradation and enhanced intestinal absorption (Date et al., 2010).

These findings indicate that SNEDDS could play a major role in enabling oral delivery of biologics, which traditionally require parenteral administration.

7.4 Applications in Herbal and Natural Compounds

Herbal drugs and phytoconstituents often exhibit poor water solubility and low bioavailability, limiting their therapeutic potential. SNEDDS has been widely applied to enhance the solubility, stability, and oral absorption of herbal compounds:

- **Curcumin:** Poorly soluble and rapidly metabolized; SNEDDS formulations improved dissolution, stability, and systemic absorption.
- **Quercetin:** Lipid-based nanoemulsions enhanced solubility and bioavailability by protecting the compound from degradation.
- **Ginsenosides, resveratrol, and essential oils:** SNEDDS improved oral bioavailability and therapeutic efficacy in preclinical studies.

Advantages of SNEDDS for herbal drugs include:

- Protection against GI degradation of labile natural compounds.
- Enhanced intestinal permeability via surfactant-mediated absorption.
- Potential for targeted delivery, particularly for lipophilic phytochemicals (Date et al., 2010).

Thus, SNEDDS provides a promising approach to modernize herbal medicines and convert poorly absorbed natural compounds into clinically viable oral formulations.

7.5 Targeted and Site-Specific Drug Delivery

SNEDDS can be tailored for targeted drug delivery, particularly for gastrointestinal or lymphatic targeting:

- **Lymphatic targeting:** Lipid-based formulations promote drug transport via chylomicrons into lymphatic circulation, useful for immunomodulatory drugs, lipophilic antivirals, and anticancer agents.
- **Colon-targeted SNEDDS:** Formulated with pH-sensitive polymers or prodrugs, allowing drug release in the colon for localized therapy of inflammatory bowel disease.

- **Site-specific absorption enhancement:** By modifying oil type, surfactant concentration, or co-surfactant, SNEDDS can be engineered to release drugs at specific GI sites, enhancing therapeutic efficacy and reducing systemic side effects (Tang et al., 2008).

7.6 Applications in Pediatric and Geriatric Formulations

SNEDDS formulations offer advantages for special populations, such as children and elderly patients, where swallowing conventional tablets may be difficult:

- SNEDDS can be incorporated into soft gelatin capsules, liquid-filled syrups, or solid self-emulsifying powders, improving patient compliance.
- Rapid emulsification in the stomach or small intestine ensures consistent drug absorption despite age-related changes in GI physiology.
- Pediatric formulations of poorly soluble drugs such as ritonavir and artemether-lumefantrine have been developed using SNEDDS technology to enhance bioavailability and ease of administration (Date et al., 2010).

7.7 Emerging Applications: Oral Delivery of Biologics and Advanced Therapies

Recent research has expanded SNEDDS applications into novel therapeutic areas:

1. **Oral vaccines:** Encapsulation of antigens in SNEDDS protects them from GI degradation and facilitates uptake by intestinal immune cells, potentially enabling oral immunization.
2. **Gene delivery:** SNEDDS combined with nucleic acids and cationic lipids can enhance cellular uptake and gene transfection efficiency.
3. **Combination therapy:** SNEDDS allow co-delivery of multiple drugs in a single nanoemulsion, improving synergistic effects and simplifying dosing regimens.
4. **Hybrid nanocarriers:** SNEDDS combined with liposomes, nanoparticles, or polymeric carriers provide multifunctional platforms for controlled release, targeting, and imaging applications.

These emerging applications highlight the flexibility of SNEDDS as a drug delivery platform, extending beyond conventional small molecule therapies (Tang et al., 2008; Date et al., 2010).

8. Recent Advances and Future Perspectives

Self-nanoemulsifying drug delivery systems (SNEDDS) have evolved significantly over the past two decades, transitioning from conventional lipid-based formulations to advanced nanocarrier platforms with enhanced stability, targeting, and therapeutic efficiency. Continuous innovation in formulation strategies, excipients, solidification techniques, and computational design tools has expanded the applications of SNEDDS, enabling them to address increasingly complex drug delivery challenges. This section discusses recent advances and explores the future perspectives of SNEDDS in pharmaceutical research and clinical practice.

8.1 Solid SNEDDS (S-SNEDDS)

Conventional SNEDDS are typically liquid formulations, which pose challenges related to stability, leakage, and patient compliance. To overcome these limitations, solid self-nanoemulsifying drug delivery systems (S-SNEDDS) have been developed, combining the advantages of solid dosage forms with the self-emulsifying properties of SNEDDS.

- **Preparation Techniques:** S-SNEDDS can be prepared using spray drying, freeze drying, adsorption onto solid carriers (e.g., silica, magnesium aluminometasilicate), and hot melt extrusion.
- **Advantages:**
  - Improved physical and chemical stability compared to liquid SNEDDS.

  - Enhanced patient compliance due to solid dosage forms (capsules, tablets, pellets).
  - Simplified packaging, transportation, and storage.
- **Applications:** Drugs such as ritonavir, simvastatin, and fenofibrate have shown improved bioavailability and stability in S-SNEDDS formulations.

S-SNEDDS represent a significant advancement in overcoming the limitations of liquid SNEDDS, making them more feasible for large-scale industrial production (Tang et al., 2008).

8.2 Novel Lipid Excipients and Surfactant Systems

Recent research has focused on novel excipients that enhance the self-emulsification process, improve solubility, and reduce surfactant-related toxicity:

- **Novel Lipid Excipients:** Medium-chain triglycerides (MCTs) have been widely used, but newer lipids such as Capryol™ 90, Labrafac™ PG, and Miglyol® 812 offer improved solubilization, stability, and lymphatic transport.
- **Advanced Surfactants:** Nonionic surfactants like Cremophor EL, Labrasol®, and Kolliphor® HS15 have been optimized to balance emulsification efficiency with reduced gastrointestinal irritation.
- **Co-surfactants:** Novel co-solvents and co-surfactants such as Transcutol P, PEG derivatives, and propylene glycol enhance drug solubilization and droplet size control.

These innovations enable the formulation of SNEDDS for highly lipophilic and poorly soluble drugs, improving both bioavailability and patient safety (Date et al., 2010).

8.3 Hybrid Nanocarriers

Combining SNEDDS with other nanocarrier technologies has emerged as a promising approach to achieve multifunctional drug delivery:

- **SNEDDS + Nanoparticles:** Encapsulation of drugs in polymeric nanoparticles within SNEDDS enhances controlled release, targeted delivery, and protection from degradation.
- **SNEDDS + Liposomes:** Hybrid SNEDDS-liposome systems combine the self-emulsifying properties of SNEDDS with the biocompatibility and membrane-fusion capabilities of liposomes, improving drug absorption and intracellular delivery.
- **SNEDDS + Solid Lipid Nanoparticles (SLNs):** These hybrid systems improve thermodynamic stability, drug loading, and pharmacokinetic profiles.

Hybrid nanocarriers allow customization of drug release profiles, site-specific delivery, and co-delivery of multiple drugs, which is especially valuable for anticancer, antiviral, and peptide-based therapeutics (Pouton, 2006).

8.4 Role of Computational Modeling and Artificial Intelligence (AI) in SNEDDS Design

The design and optimization of SNEDDS have traditionally relied on trial-and-error methods, which are time-consuming and resource-intensive. Recent advances in computational modeling and AI have transformed formulation development:

- **Molecular Dynamics Simulations:** Predict interactions between drugs, lipids, and surfactants, enabling rational selection of excipients for optimal solubilization and self-emulsification.
- **Quantitative Structure-Activity Relationship (QSAR) Models:** Help predict drug solubility and partitioning behavior in different lipid and surfactant systems.

- **Machine Learning Algorithms:** Optimize SNEDDS formulations by analyzing large datasets of droplet size, emulsification efficiency, and bioavailability, reducing the need for extensive experimental trials.
- **Predictive Pharmacokinetic Modeling:** Assists in forecasting absorption, lymphatic transport, and systemic exposure, allowing early-stage formulation refinement.

These tools accelerate SNEDDS development, reduce costs, and improve the precision of formulation design, aligning with modern trends in pharmaceutical informatics and rational drug delivery (Date et al., 2010).

8.5 Regulatory and Industrial Perspectives

The widespread adoption of SNEDDS in pharmaceutical industry has necessitated regulatory guidelines and quality control strategies:

- **Regulatory Considerations:**
  - Emphasis on droplet size, polydispersity index, zeta potential, and thermodynamic stability.
  - Safety evaluation of surfactants and co-surfactants used in SNEDDS formulations.
  - Bioequivalence studies for generic SNEDDS products.
- **Industrial Challenges:**
  - Scale-up of SNEDDS manufacturing requires consistent droplet size and emulsification properties.
  - Liquid SNEDDS pose challenges in capsule filling and stability, driving the need for S-SNEDDS or solidified SNEDDS.

Regulatory compliance and industrial scalability are critical for successful translation of laboratory SNEDDS into clinically approved formulations (Pouton, 2006).

8.6 Future Perspectives

The future of SNEDDS is expected to focus on advanced, patient-friendly, and multifunctional drug delivery systems:

1. **Oral Delivery of Biologics:**
   - SNEDDS can enable oral delivery of peptides, proteins, and nucleic acids, which traditionally require injection.
   - Protection from enzymatic degradation and enhanced lymphatic transport are key advantages.
2. **Personalized Medicine:**
   - Customizable SNEDDS formulations can be tailored to individual patient needs, age, and disease state, optimizing therapeutic outcomes.
3. **Targeted and Stimuli-Responsive SNEDDS:**
   - Incorporating pH-sensitive or enzyme-responsive excipients can allow site-specific drug release in the GI tract.
   - Targeted lymphatic delivery for immunotherapy and anticancer drugs is a promising direction.
4. **Integration with Advanced Manufacturing:**
   - Techniques such as 3D printing, hot-melt extrusion, and continuous manufacturing can streamline SNEDDS production, ensuring consistency and scalability.
5. **Green and Sustainable Formulations:**
   - Future SNEDDS development may emphasize biodegradable, non-toxic lipids and surfactants, aligning with sustainable pharmaceutical practices.

Overall, SNEDDS are poised to become next-generation oral drug delivery platforms, capable of addressing complex solubility, stability, and absorption challenges in both small molecules and biologics.

References:

1. Akhlaq, R., Harwansh, R., Aamir, M., Hussain, S., & Hussain, A. (2021). Oral lipid-based drug delivery systems (LBDDS): Formulation, characterization and application—A review. *Current Drug Delivery, 18*(4), 1–14. https://doi.org/10.2174/1567201818666210706163017
2. Haarika, B., Nikitha, S., Madhuri, P., & Prasanthi, R. (2023). A review on self-nanoemulsifying drug delivery systems (SNEDDS). *International Journal of Current Advanced Research, 12*(3), 1235–1245. https://www.journalijcar.org/issues/review-self-nano-emulsifying-drug-delivery-systems-snedds
3. Ravi, A., Mohanan, J., Chalil, A., & Karakkunnummal, F. N. (2023). Advances in self-nanoemulsifying drug delivery systems: Mechanistic insights and formulation strategies. *Journal of Drug Delivery and Therapeutics, 15*(8), 45–58. https://doi.org/10.22270/jddt.v15i8.7303
4. Kannan, S., Singh, R., & Patel, N. (2023). Unlocking the potential: Synergistic effects of solid SNEDDS and lyophilized solid dispersion to enhance stability attributes. *EXCLI Journal, 22*, 880–903. https://doi.org/10.17179/excli2023-6345
5. Pharmaceuticals. (2023). Formulation and evaluation of SNEDDS loaded with original lipophenol for the oral route to prevent dry AMD and Stargardt's disease. *Pharmaceuticals, 14*(5), 1029. https://doi.org/10.3390/ph14051029
6. Balakrishnan, P., Lee, B. J., Oh, D. H., Kim, J. O., Hong, M. J., Jee, J. P., Kim, J. A., Yoo, B. K., Woo, J. S., & Yong, C. S. (2009). Enhanced oral bioavailability of dexibuprofen by a novel solid self-nanoemulsifying drug delivery system (solid SNEDDS). *European Journal of Pharmaceutics and Biopharmaceutics, 72*(3), 539–545. https://doi.org/10.1016/j.ejpb.2009.03.002
7. Constantinides, P. P. (1995). Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. *Pharmaceutical Research, 12*(11), 1561–1572. https://doi.org/10.1023/A:1016207823944
8. Date, A. A., Desai, N., Dixit, R., & Nagarsenker, M. S. (2010). Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances. *Nanomedicine, 5*(10), 1595–1616. https://doi.org/10.2217/nnm.10.126
9. Kommuru, T. R., Gurley, B., Khan, M. A., & Reddy, I. K. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. *International Journal of Pharmaceutics, 212*(2), 233–246. https://doi.org/10.1016/S0378-5173(00)00628-9
10. Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. P. (2007). Lipid-based formulations as enabling systems for oral delivery of poorly water-soluble drugs. *Advanced Drug Delivery Reviews, 60*(6), 673–691. https://doi.org/10.1016/j.addr.2007.10.010
11. Pouton, C. W. (1997). Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews, 25*(1), 47–58. https://doi.org/10.1016/S0169-409X(96)00490-5
12. Shah, N. H., Carvajal, M. T., Patel, C. I., Infeld, M. H., & Malick, A. W. (1994). Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. *International Journal of Pharmaceutics, 106*(1), 15–23. https://doi.org/10.1016/0378-5173(94)90271-2
13. Singh, B., Bandopadhyay, S., Kapil, R., Singh, R., & Katare, O. P. (2009). Self-emulsifying drug delivery systems (SEDDS): Formulation development, characterization, and applications. *Critical Reviews in Therapeutic Drug Carrier Systems, 26*(5), 427–521. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i5.10
14. Balakrishnan, P., Lee, B. J., Oh, D. H., Kim, J. O., Hong, M. J., Jee, J. P., Kim, J. A., Yoo, B. K., Woo, J. S., & Yong, C. S. (2009). Enhanced oral bioavailability of dexibuprofen by a novel solid self-nanoemulsifying drug delivery system (solid SNEDDS). *European Journal of Pharmaceutics and Biopharmaceutics, 72*(3), 539–545. https://doi.org/10.1016/j.ejpb.2009.03.002
15. Date, A. A., Desai, N., Dixit, R., & Nagarsenker, M. S. (2010). Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances. *Nanomedicine, 5*(10), 1595–1616. https://doi.org/10.2217/nnm.10.126
16. Kommuru, T. R., Gurley, B., Khan, M. A., & Reddy, I. K. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment.

International Journal of Pharmaceutics, 212(2), 233–246. https://doi.org/10.1016/S0378-5173(00)00628-9

17. Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. P. (2007). Lipid-based formulations as enabling systems for oral delivery of poorly water-soluble drugs. *Advanced Drug Delivery Reviews, 60*(6), 673–691. https://doi.org/10.1016/j.addr.2007.10.010
18. Pouton, C. W. (1997). Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews, 25*(1), 47–58. https://doi.org/10.1016/S0169-409X(96)00490-5
19. Singh, B., Bandopadhyay, S., Kapil, R., Singh, R., & Katare, O. P. (2009). Self-emulsifying drug delivery systems (SEDDS): Formulation development, characterization, and applications. *Critical Reviews in Therapeutic Drug Carrier Systems, 26*(5), 427–521. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i5.10
20. Date, A. A., Desai, N., Dixit, R., & Nagarsenker, M. S. (2010). Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances. *Nanomedicine, 5*(10), 1595–1616. https://doi.org/10.2217/nnm.10.126
21. Kommuru, T. R., Gurley, B., Khan, M. A., & Reddy, I. K. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. *International Journal of Pharmaceutics, 212*(2), 233–246. https://doi.org/10.1016/S0378-5173(00)00628-9
22. Pouton, C. W. (2006). Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews, 60*(6), 625–637. https://doi.org/10.1016/j.addr.2007.01.004
23. Singh, B., Bandopadhyay, S., Kapil, R., Singh, R., & Katare, O. P. (2009). Self-emulsifying drug delivery systems (SEDDS): Formulation development, characterization, and applications. *Critical Reviews in Therapeutic Drug Carrier Systems, 26*(5), 427–521. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i5.10
24. Tang, B., Cheng, G., Gu, J. C., & Xu, C. H. (2008). Development of solid self-emulsifying drug delivery systems: Preparation techniques and dosage forms. *Drug Discovery Today, 13*(13–14), 606–612. https://doi.org/10.1016/j.drudis.2008.05.003
25. Date, A. A., Desai, N., Dixit, R., & Nagarsenker, M. S. (2010). Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances. *Nanomedicine, 5*(10), 1595–1616. https://doi.org/10.2217/nnm.10.126
26. Kommuru, T. R., Gurley, B., Khan, M. A., & Reddy, I. K. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. *International Journal of Pharmaceutics, 212*(2), 233–246. https://doi.org/10.1016/S0378-5173(00)00628-9
27. Pouton, C. W. (2006). Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews, 60*(6), 625–637. https://doi.org/10.1016/j.addr.2007.01.004
28. Singh, B., Bandopadhyay, S., Kapil, R., Singh, R., & Katare, O. P. (2009). Self-emulsifying drug delivery systems (SEDDS): Formulation development, characterization, and applications. *Critical Reviews in Therapeutic Drug Carrier Systems, 26*(5), 427–521. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i5.10
29. Tang, B., Cheng, G., Gu, J. C., & Xu, C. H. (2008). Development of solid self-emulsifying drug delivery systems: Preparation techniques and dosage forms. *Drug Discovery Today, 13*(13–14), 606–612. https://doi.org/10.1016/j.drudis.2008.05.003
30. Kommuru, T. R., Gurley, B., Khan, M. A., & Reddy, I. K. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. *International Journal of Pharmaceutics, 212*(2), 233–246. https://doi.org/10.1016/S0378-5173(00)00628-9
31. Tang, B., Cheng, G., Gu, J. C., & Xu, C. H. (2008). Development of solid self-emulsifying drug delivery systems: Preparation techniques and dosage forms. *Drug Discovery Today, 13*(13–14), 606–612. https://doi.org/10.1016/j.drudis.2008.05.003
32. Pouton, C. W. (2006). Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews, 60*(6), 625–637. https://doi.org/10.1016/j.addr.2007.01.004

33. Date, A. A., Desai, N., Dixit, R., & Nagarsenker, M. S. (2010). Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances. *Nanomedicine, 5*(10), 1595–1616. https://doi.org/10.2217/nnm.10.126
34. Kommuru, T. R., Gurley, B., Khan, M. A., & Reddy, I. K. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. *International Journal of Pharmaceutics, 212*(2), 233–246. https://doi.org/10.1016/S0378-5173(00)00628-9
35. Tang, B., Cheng, G., Gu, J. C., & Xu, C. H. (2008). Development of solid self-emulsifying drug delivery systems: Preparation techniques and dosage forms. *Drug Discovery Today, 13*(13–14), 606–612. https://doi.org/10.1016/j.drudis.2008.05.003
36. Pouton, C. W. (2006). Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews, 60*(6), 625–637. https://doi.org/10.1016/j.addr.2007.01.004